Solid Biosciences Ownership
| SLDB Stock | USD 4.60 0.10 2.13% |
Shares in Circulation | First Issued 2017-06-30 | Previous Quarter 41 M | Current Value 41 M | Avarage Shares Outstanding 10.8 M | Quarterly Volatility 12.9 M |
Solid |
Solid Stock Ownership Analysis
About 62.0% of the company shares are owned by institutional investors. The book value of Solid Biosciences was at this time reported as 3.39. The company recorded a loss per share of 3.06. Solid Biosciences LLC had not issued any dividends in recent years. The entity had 1:15 split on the 28th of October 2022. Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Solid Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people. To find out more about Solid Biosciences LLC contact Alexander Cumbo at 617 337 4680 or learn more at https://www.solidbio.com.Besides selling stocks to institutional investors, Solid Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Solid Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Solid Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Solid Biosciences Quarterly Liabilities And Stockholders Equity |
|
Solid Biosciences Insider Trades History
Less than 1% of Solid Biosciences LLC are currently held by insiders. Unlike Solid Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Solid Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Solid Biosciences' insider trades
Solid Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Solid Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Solid Biosciences LLC backward and forwards among themselves. Solid Biosciences' institutional investor refers to the entity that pools money to purchase Solid Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2024-12-31 | 719.8 K | Redmile Group, Llc | 2024-12-31 | 615.2 K | Geode Capital Management, Llc | 2024-12-31 | 509.8 K | Monashee Investment Management Llc | 2024-12-31 | 480 K | State Street Corp | 2024-12-31 | 432.2 K | Alyeska Investment Group, L.p. | 2024-12-31 | 346.4 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 264.1 K | Laurion Capital Management Lp | 2024-12-31 | 255.1 K | Nuveen Asset Management, Llc | 2024-12-31 | 197.9 K | Perceptive Advisors Llc | 2024-12-31 | 6.9 M | Ra Capital Management, Llc | 2024-12-31 | 4.3 M |
Solid Biosciences LLC Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Solid Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Solid Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Solid Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Solid Biosciences Outstanding Bonds
Solid Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Solid Biosciences LLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Solid bonds can be classified according to their maturity, which is the date when Solid Biosciences LLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Solid Biosciences Corporate Filings
F4 | 13th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 6th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 25th of February 2025 Other Reports | ViewVerify | |
F3 | 19th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.